All News

From biosimilars to artificial intelligence, these are the trends poised to take community pharmacy by storm.

Make mental health a priority.

Readers, we want to hear from you.

A look at what’s to come in the October issue of Drug Topics®

SingleCare's 4th annual celebration of the best in pharmacy, from pharmacists to pharmacy technicians and teams across the United States has been announced.

Your weekly roundup of the latest news from Drug Topics®.

The move is meant to expand access to reproductive health care for women in the state.

The new guidance aims to improve supply for harm reduction programs.

Now with the brand name Relyvrio, the new therapy should be available within four to six weeks. It will have a wholesale acquisition cost of $158,000 per year.

Erickson shares her tips on managing burnout as a student pharmacist.

The announcement of positive phase 3 results for the investigational Alzheimer’s disease drug comes against a backdrop of Aduhelm flaming out. Both drugs are predicated on the theory that Alzheimer’s is caused by beta-amyloid deposits.

Take a look back at our most popular news from September 2022.

However, researchers found that only a small percentage of plans use available real-world evidence studies and economic evaluations in their coverage policies.

The future of independent pharmacy requires the combination of what makes independent pharmacy special and the digital landscape found elsewhere in retail.

Positive effects emerge when patients get medical care, avoid deadly fentanyl-laced street drugs.

Your weekly roundup of the latest news from Drug Topics®.

The National Commission on Correctional Health Care and 166 other national organizations recently signed a letter to Senate leadership advocating for increased access to buprenorphine.

Hospitalization, disability, having private high-deductible, Medicare Advantage, or no coverage were risk factors associated with medical debt.

ViiV Healthcare reports long-term positive results for its drug, Rukobia (fostemsavir).

The harm caused by weight-loss drugs have overwhelmed any benefit they may have. The repurposed diabetes drugs like Wegovy (semaglutide) have a strong safety profile.

Your weekly roundup of the latest news from Drug Topics®.

Your weekly roundup of the latest news from Drug Topics®.

Your weekly roundup of the latest news from Drug Topics®.

Survey participants said their drug costs have gone up and almost a third had trouble paying for food and housing because of high drug costs.

This recall of propofol because of particulates seen in vials follows a previous one in July 2022.

Take a look back at our most popular news from August 2022.

Medicare users will see prescription drug pricing reform thanks to the Inflation Reduction Act.

Your weekly roundup of the latest news from Drug Topics®.